Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Long-term clinical results of limbal conjunctival autograft versus amniotic membrane transplantation in pterygium surgery

Poster Details

First Author: H.Kim SOUTH KOREA

Co Author(s):    S. Gang              

Abstract Details



Purpose:

To compare the long term clinical outcome of limbal conjunctival autograft versus amniotic membrane transplantation in surgically treated pterygium patients.

Setting:

Department of Ophthalmology, Catholic University of Daegu, Daegu, Korea

Methods:

116 cases of pterygium in patients older than 50 years were surgically excised and received either limbal conjunctival autograft or amniotic membrane transplantation. Mean follow-up period was 48 months. All patients were examined for recurrence, which was graded from G0 to G3, and complications such as delayed epithelial wound healing and granuloma formation.

Results:

In limbal conjunctival autograft group, 52 out of 60 cases showed no recurrence(grade 0), and 5 cases of grade 1 recurrence and 3 cases of grade 2 were observed. On the contrary, 43 out of 56 cases in amniotic membrane transplantation group showed no recurrence, and 7 cases of grade 2 recurrence and 6 cases of grade 3 recurrence were observed. Conjunctival granuloma formation was occurred in 4 cases in amniotic membrane transplantation group and none in limbal conjunctival autograft group. Epithelial wound healing is not delayed in both group.

Conclusions:

Both limbal conjunctival autograft and amniotic membrane transplantation can be safe and effective adjunctive treatments for primary pterygium. However, limbal conjunctival autograft has a lower recurrence rate than amniotic membrane transplantation for long term follow up period. Limbal conjunctival autograft appears to be a more effective technique to reduce the recurrence after pterygium excision.

Financial Disclosure:

NONE

Back to previous